Showing 1491-1500 of 4936 results for "".
Janssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeSummer AAD Highlights, Alopecia Areata Discovery
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-summer-aad-highlights-alopecia-areata-discovery/18846/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, new research that suggests emerging biologic therapies could help treat alopecia areata. Plus, updates on atopic dermatitis and eczema, hands-on education, and Kybella from the AAD Summer meeting. AndDr. Joel Schlessinger discusses the importance of clinical research in your practice
https://practicaldermatology.com/topics/practice-management/dr-joel-schlessinger-discusses-the-importance-of-clinical-research-in-your-practice/19135/With hundreds of new products, procedures and technologies becoming available every day, it is important to keep up with the changing medical world. One way to do this is through clinical research at your practice. In this video, Dr. Joel Schlessinger discusses how he began his clinical research stuDermWireTV: Ped Derm Salaries; Skin Cancer Symposium Kicks Off; Pandemic Self Care Stats
https://practicaldermatology.com/topics/practice-management/dermwiretv-ped-derm-salaries-skin-cancer-symposium-kicks-off-pandemic-self-care-stats/19910/According to the Society for Pediatric Dermatology’s 2020 Pediatric Dermatology Physician Compensation Report, salaries have increased 37% since 2014. Pediatric dermatologist Mercedes Gonzalez, MD comments. The inaugural Skin Cancer Symposium is underway and the Symposium for Inflammatory Disease kiDermWireTV: Staff Vaccinations, Dupilumab Data, Rosacea Resource, Sensitive Skin Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-staff-vaccinations-dupilumab-data-rosacea-resource-sensitive-skin-week/19907/Most physicians have had a chance to be vaccinated, but staff may be a different story. Some practices are struggling with policies for mandated staff vaccines. The National Rosacea Society has updated its most popular educational booklet, “Understanding Rosacea.” New data highlight the potential imNew SEO Trends Dermatologists Should Anticipate in 2021
https://practicaldermatology.com/topics/practice-management/new-seo-trends-dermatologists-should-anticipate-in-2021/19900/Dermatology online marketing will have a surge of possible business in 2021 as people start moving back to requesting and seeking medical care again, especially once COVID-19 vaccines become widespread. Getting ahead of the SEO search curve now will give your office the advantage before the demand mDermWireTV: Noble Educates on Self-Injection; AAD and DEF Meeting Updates
https://practicaldermatology.com/topics/practice-management/dermwiretv-noble-educates-on-self-injection-aad-and-def-meeting-updates/19645/Participants in a study by the company Noble show that the vast majority of patients—92%—would prefer to bring home a training device to practice with prior to starting self-injection. Noble creates trainers for autoinjectors intended to increase patient confidence and autonomy with self-managed treAAD Wrap: What To Know from Dermatology’s Biggest Meeting
https://practicaldermatology.com/issues/april-2025/aad-wrap-what-to-know-from-dermatologys-biggest-meeting/35623/The 2025 American Academy of Dermatology (AAD) Annual Meeting brought together the dermatology community this past March to exchange groundbreaking research, innovative treatments, and technological advancements. For 4 days in Orlando, the meeting served as the hub of the dermatology profession, delThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeDERM2024 Meeting Wrap-Up
https://practicaldermatology.com/conferences/derm2024/derm2024-meeting-wrap/26974/DERM2024 Meeting Wrap-Up